IRIS - Res&Arch Institutional Research Information System - Research & Archive

ROTI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.127
EU - Europa 874
AS - Asia 278
SA - Sud America 2
AF - Africa 1
Totale 2.282
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.124
IE - Irlanda 238
SE - Svezia 175
IT - Italia 157
SG - Singapore 92
HK - Hong Kong 74
UA - Ucraina 70
FI - Finlandia 66
VN - Vietnam 53
RU - Federazione Russa 47
CN - Cina 42
DE - Germania 26
GB - Regno Unito 25
RO - Romania 16
KR - Corea 12
FR - Francia 11
CH - Svizzera 9
BE - Belgio 7
CZ - Repubblica Ceca 6
NL - Olanda 6
PL - Polonia 6
AT - Austria 4
GR - Grecia 3
BR - Brasile 2
CA - Canada 2
LB - Libano 2
UZ - Uzbekistan 2
BG - Bulgaria 1
CI - Costa d'Avorio 1
ES - Italia 1
IN - India 1
MX - Messico 1
Totale 2.282
Salva come PNG Salva come JPEG
Città #
Chandler 248
Dublin 238
San Mateo 164
Boardman 82
Hong Kong 74
Singapore 62
Ann Arbor 61
Altamura 57
Medford 55
Princeton 54
Dong Ket 53
Perugia 53
Wilmington 48
Lawrence 44
Andover 38
Jacksonville 37
Helsinki 17
Beijing 15
Saint Petersburg 15
Bucharest 14
Seoul 12
Woodbridge 9
Assisi 8
Santa Clara 8
Ashburn 7
Brussels 7
Munich 7
Norwalk 7
Boston 6
Dearborn 6
Des Moines 6
Los Angeles 6
New York 6
Dallas 5
Bastia 4
Frankfurt Am Main 4
Houston 4
San Paolo di Civitate 4
Auburn Hills 3
Brno 3
Moscow 3
Den Haag 2
Falls Church 2
Foligno 2
Macerata 2
Melissa 2
Milan 2
Olomouc 2
Parma 2
Shanghai 2
Timisoara 2
West Jordan 2
Abidjan 1
Amsterdam 1
Birmingham 1
Falkenstein 1
Guangzhou 1
Huskvarna 1
Madrid 1
Montreal 1
Nanjing 1
Napoli 1
Nuneaton 1
Nürnberg 1
Paris 1
Redmond 1
Redwood City 1
Secaucus 1
Toronto 1
Vienna 1
Totale 1.594
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 129
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 112
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 85
Acute lymphoblastic leukaemia in Noonan syndrome 80
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 76
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 72
Genetic pathways in low-and high-grade HCV-related lymphomas are different 67
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 62
Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in Acute Myeloid Leukemia 62
DHPLC analysis of NPM1 mutations in adult primary AML. 58
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 58
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML) 58
Angiopoietins expression by human myeloma cells. 57
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia 56
Different genomic imbalances in low- and high-grade HCV-related lymphomas 53
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 51
Quantitative detection of NPM1 mutations as marker of minimal residual disease (MRD) in the large majority of AML with normal karyotype 48
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 48
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 47
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. 47
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 45
Denaturing high performance liquid chromatography analysis of npm1 mutations in adult primary acute myeloid leukemia. 43
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 41
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement 40
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. 39
Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL 39
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 38
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML). 38
Il-7 is induced by il-6 in human myeloma cells: role in multiple myeloma. 36
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 36
Mutational analisys of JAK2 VAL617PHE in a new series of chronic myelomonocytic leukemia and related atypical myeloproliferative disorders 36
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 36
Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. 34
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6. 33
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 33
Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies 32
Molecular cytogenetic studies of myelodysplastic/ myloproliferative disease. 29
NPM1 haploinsufficiency in MDS/AML with del(5q)/monosomy 5 29
Quantitative detection of NPM1 mutations as marker of minimal residual disease (MRD) in the large majority of AML with normal karyotype. 29
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma. 29
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. 28
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 28
Modulating Notch1 With Signature-based Small Molecule Library Screening 26
Osteopontin is produced by human multiple myeloma cells. 26
Identification of AML1-ETO modulators by chemical genomics. 26
Multiple Myeloma Patient with unusual extramedullary involvement 25
NPM1 gene mutations in acute myeloid leukemia. 24
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: Potential relationship with myeloma-induced angiogenesis 22
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. 22
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. 21
Targeting NOTCH1 in hematopoietic malignancy. 20
NPM1 monoallelic deletion in a subgroup of MDS/AML with del(5q) or monosomy 5 and complex karyotype 19
New Approaches to Target T-ALL 18
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. 16
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 14
Genetic and proteomic approaches to identify cancer drug targets. 14
Totale 2.390
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.213
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202094 0 0 11 1 10 7 9 5 14 19 4 14
2020/2021313 0 10 17 7 116 28 13 3 27 13 18 61
2021/2022527 9 115 11 30 24 3 1 158 7 22 71 76
2022/2023780 56 155 5 72 47 76 0 38 308 0 19 4
2023/2024312 27 26 20 12 2 3 63 0 19 10 44 86
2024/2025122 16 72 34 0 0 0 0 0 0 0 0 0
Totale 2.390